50 Years Old And Still Bounding Over The Counter: Kline's Healthcare Practice Continues To Deliver Unmatched OTC Market Intelligence
PARSIPPANY, N.J., Sept. 24, 2013 /PRNewswire/ -- With over half a century of market insights on the U.S. consumer healthcare market, Kline & Company expects that new paradigm shifts in regulations, retail, and technology will create new opportunities for medications to move along the Rx-to-OTC continuum and more growth prospects for the U.S. OTC market. Additionally, with the OTC medication market in the United States nearing $23 billion in 2012 alone and with the FDA - through its recent NSURE (Nonprescription Safe Use Regulatory Expansion) initiative - showing encouraging indications that it is becoming more receptive to allowing more Rx-to-OTC switches, the U.S. OTC market is fast returning to pre-recession health.
Celebrating its 50th anniversary, Kline's distinguished Nonprescription Drugs USA report continues to provide the most comprehensive market intelligence expanding its longstanding OTC drugs industry know-how to include indispensable research on related topics including Natural OTCs, OTC Retailing, OTC Innovations, Impact of Recessions on the U.S. OTC Market, OTC Drugs: U.S. Competitor Cost Structures, OTC Consumer/Shopper Insights and a series of reports on Rx-to-OTC Switch .
In recent years, the U.S. OTC market has been hindered by significant product recalls by major players, with the resultant vacuum - abetted by recession-affected ever cost-conscious consumers - largely claimed by private-label alternatives. Laura Mahecha, industry manager at Kline's Healthcare Practice, adds, "The impact and profound magnitude of ongoing economic uncertainty is borne out by more than half of respondents in a recent Kline survey disclosing that they'd changed how they purchased OTC drugs. Specifically, nearly a quarter of those surveyed choose private label OTC drugs whenever possible because of their perceived cost advantage."
Despite the stronghold private-label products have on the market and the highly competitive nature of this market, there is still room for OTC brands to grow and prosper in the coming years with increased focus from major companies on innovations, new product launches and line extensions, and strategic marketing plans.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts